Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCMNASDAQ:ILMNNASDAQ:ISRGNASDAQ:PODD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$63.40+2.9%$79.63$57.52▼$141.99$24.96B1.54.11 million shs916,007 shsILMNIllumina$73.68+0.3%$95.52$69.55▼$156.66$11.77B1.382.23 million shs419,903 shsISRGIntuitive Surgical$485.30+4.7%$542.98$364.17▼$616.00$173.34B1.551.55 million shs529,393 shsPODDInsulet$256.24+0.0%$269.47$160.19▼$289.46$18.10B1.3713,933 shs132,121 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom+3.01%-9.75%-20.82%-22.33%-55.64%ILMNIllumina-0.96%-7.42%-15.20%-47.19%-42.50%ISRGIntuitive Surgical+2.67%-6.39%-10.54%-12.83%+19.37%PODDInsulet+4.47%-2.43%+1.76%-3.55%+55.29%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXCMDexCom4.8566 of 5 stars4.43.00.04.74.12.51.9ILMNIllumina4.688 of 5 stars4.25.00.04.22.91.71.3ISRGIntuitive Surgical4.754 of 5 stars4.33.00.04.03.62.51.9PODDInsulet4.2607 of 5 stars3.42.00.04.93.50.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.89Moderate Buy$99.8257.44% UpsideILMNIllumina 2.48Hold$140.6590.89% UpsideISRGIntuitive Surgical 2.67Moderate Buy$611.8626.08% UpsidePODDInsulet 2.82Moderate Buy$292.0613.98% UpsideCurrent Analyst Ratings BreakdownLatest ISRG, PODD, DXCM, and ILMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025ILMNIlluminaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$128.00 ➝ $112.004/7/2025ILMNIlluminaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$90.00 ➝ $85.003/21/2025DXCMDexComCfra ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold3/18/2025ISRGIntuitive SurgicalRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$707.00 ➝ $600.003/17/2025ISRGIntuitive SurgicalErste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/17/2025ISRGIntuitive SurgicalTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$666.00 ➝ $605.003/12/2025ILMNIlluminaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$247.00 ➝ $128.003/11/2025ILMNIlluminaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight3/11/2025ILMNIlluminaStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$156.00 ➝ $156.003/11/2025ILMNIlluminaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$135.00 ➝ $115.003/8/2025DXCMDexComWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 4/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.03B6.16$1.60 per share39.75$5.38 per share11.78ILMNIllumina$4.37B2.67$3.56 per share20.72$14.98 per share4.92ISRGIntuitive Surgical$8.35B20.70$6.39 per share75.93$46.41 per share10.46PODDInsulet$2.07B8.69$3.37 per share75.96$10.49 per share24.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$576.20M$1.4344.5125.772.3014.29%30.14%10.11%5/1/2025 (Estimated)ILMNIllumina-$1.22B-$7.68N/A14.281.60-27.95%13.37%5.49%5/1/2025 (Estimated)ISRGIntuitive Surgical$2.32B$6.4175.9263.605.8527.81%14.55%12.88%4/22/2025 (Estimated)PODDInsulet$206.30M$5.7944.5051.563.6220.19%24.46%8.33%5/8/2025 (Estimated)Latest ISRG, PODD, DXCM, and ILMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025N/ADXCMDexCom$0.33N/AN/AN/A$1.02 billionN/A5/1/2025N/AILMNIllumina$0.94N/AN/AN/A$1.03 billionN/A4/22/2025N/AISRGIntuitive Surgical$1.71N/AN/AN/A$2.19 billionN/A2/20/2025Q4 2024PODDInsulet$1.00$1.15+$0.15$1.39$582.02 million$597.50 million2/13/2025Q4 2024DXCMDexCom$0.50$0.45-$0.05$0.38$1.10 billionN/A2/6/2025Q4 2024ILMNIllumina$0.92$0.86-$0.06$1.17$1.08 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/AILMNIlluminaN/AN/AN/AN/AN/AISRGIntuitive SurgicalN/AN/AN/AN/AN/APODDInsuletN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.591.471.28ILMNIllumina0.631.771.42ISRGIntuitive SurgicalN/A4.073.22PODDInsulet1.213.682.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%ILMNIllumina89.42%ISRGIntuitive Surgical83.64%PODDInsuletN/AInsider OwnershipCompanyInsider OwnershipDXCMDexCom0.30%ILMNIllumina0.17%ISRGIntuitive Surgical0.70%PODDInsulet0.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom7,600392.11 million389.60 millionOptionableILMNIllumina9,030158.40 million158.13 millionOptionableISRGIntuitive Surgical12,100356.18 million352.97 millionOptionablePODDInsulet2,60070.23 million69.82 millionOptionableISRG, PODD, DXCM, and ILMN HeadlinesRecent News About These CompaniesInsulet Co. (NASDAQ:PODD) Shares Acquired by Federated Hermes Inc.April 8 at 6:33 AM | marketbeat.comArrowstreet Capital Limited Partnership Invests $9.82 Million in Insulet Co. (NASDAQ:PODD)April 8 at 3:54 AM | marketbeat.comInsulet launches Omnipod 5 in CanadaApril 8 at 1:42 AM | drugdeliverybusiness.comInsulet (NasdaqGS:PODD) Launches Omnipod 5 In Canada As Shares Dip 7%April 8 at 1:42 AM | finance.yahoo.com1,700 Shares in Insulet Co. (NASDAQ:PODD) Purchased by Katamaran Capital LLPApril 7 at 6:32 AM | marketbeat.comRhenman & Partners Asset Management AB Purchases 17,000 Shares of Insulet Co. (NASDAQ:PODD)April 7 at 6:23 AM | marketbeat.comO Shaughnessy Asset Management LLC Buys 1,610 Shares of Insulet Co. (NASDAQ:PODD)April 7 at 4:01 AM | marketbeat.comGeode Capital Management LLC Raises Position in Insulet Co. (NASDAQ:PODD)April 6 at 4:42 AM | marketbeat.comNational Bank of Canada FI Increases Stock Position in Insulet Co. (NASDAQ:PODD)April 5 at 4:41 AM | marketbeat.comCalifornia Public Employees Retirement System Has $29.20 Million Position in Insulet Co. (NASDAQ:PODD)April 5 at 4:07 AM | marketbeat.comOrion Portfolio Solutions LLC Sells 2,373 Shares of Insulet Co. (NASDAQ:PODD)April 5 at 3:55 AM | marketbeat.comCinctive Capital Management LP Acquires Shares of 52,130 Insulet Co. (NASDAQ:PODD)April 4, 2025 | marketbeat.comPictet Asset Management Holding SA Has $10.96 Million Position in Insulet Co. (NASDAQ:PODD)April 4, 2025 | marketbeat.comInsulet Corp (PODD) Announces Q1 2025 Financial Results Release DateApril 3, 2025 | gurufocus.comInsulet to Announce First Quarter 2025 Financial Results on May 8, 2025April 3, 2025 | businesswire.comTrexquant Investment LP Buys 13,996 Shares of Insulet Co. (NASDAQ:PODD)April 3, 2025 | marketbeat.comAllstate Corp Takes $545,000 Position in Insulet Co. (NASDAQ:PODD)April 3, 2025 | marketbeat.comInsulet Co. (NASDAQ:PODD) Shares Sold by Korea Investment CORPApril 2, 2025 | marketbeat.comInsulet Stock: Is PODD Outperforming the Healthcare Sector?April 1, 2025 | msn.comInsulet Co. (NASDAQ:PODD) Shares Purchased by Mitsubishi UFJ Asset Management Co. Ltd.April 1, 2025 | marketbeat.comBrokerages Set Insulet Co. (NASDAQ:PODD) PT at $292.06April 1, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeISRG, PODD, DXCM, and ILMN Company DescriptionsDexCom NASDAQ:DXCM$63.40 +1.77 (+2.88%) As of 10:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Illumina NASDAQ:ILMN$73.68 +0.23 (+0.31%) As of 10:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.Intuitive Surgical NASDAQ:ISRG$485.30 +21.68 (+4.68%) As of 10:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.Insulet NASDAQ:PODD$256.24 +0.01 (+0.00%) As of 10:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains? Options Activity Points to More Volatility for Palantir Stock NVIDIA Stock: Oversold, Undervalued — How Low Can It Go? MicroStrategy Sees Insider Buy-Sell Action in Q1 Buffett’s Next Oil Bet: Why Occidental Is Different Springing Dividends: 3 Dividend Boosters to Watch Now Alibaba Caught in Tariff Crossfire: Is It Time to Buy? Can Solid Biosciences Challenge Sarepta in the DMD Market? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
